E. Ohman J or Asset Management AB Purchases Shares of 160,000 Denali Therapeutics Inc. $DNLI

E. Ohman J or Asset Management AB acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) during the second quarter, Holdings Channel reports. The institutional investor acquired 160,000 shares of the company’s stock, valued at approximately $4,115,000.

Several other institutional investors have also recently modified their holdings of DNLI. Norges Bank acquired a new stake in shares of Denali Therapeutics during the fourth quarter worth about $84,525,000. ADAR1 Capital Management LLC increased its holdings in Denali Therapeutics by 3,490.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after buying an additional 1,819,339 shares during the period. Goldman Sachs Group Inc. raised its position in Denali Therapeutics by 77.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock worth $63,329,000 after buying an additional 1,672,098 shares during the last quarter. Temasek Holdings Private Ltd raised its position in Denali Therapeutics by 30.9% during the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after buying an additional 1,657,142 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its stake in Denali Therapeutics by 28.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after acquiring an additional 1,615,565 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $25.00 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The stock has a market capitalization of $3.97 billion, a PE ratio of -8.80 and a beta of 1.01. Denali Therapeutics Inc. has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The company has a fifty day moving average of $23.63 and a two-hundred day moving average of $21.35.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter last year, the business posted ($0.72) EPS. As a group, research analysts forecast that Denali Therapeutics Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on DNLI shares. Sanford C. Bernstein reaffirmed a “hold” rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Leerink Partners decreased their target price on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Friday, July 17th. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a research report on Monday, July 13th. They set an “overweight” rating and a $29.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a research note on Monday, May 11th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $35.92.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.